Quantitative analysis of the Ah receptor/cytochrome P450CYP1B1/CYP1A1 signalling pathway

被引:37
作者
McFadyen, MCE [1 ]
Rooney, PH
Melvin, WT
Murray, GI
机构
[1] Univ Aberdeen, Dept Pathol, Aberdeen AB25 2ZD, Scotland
[2] Univ Aberdeen, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland
关键词
cytochrome P450; CYP1B1; aryl hydrocarbon receptor; differential expression; quantitative real-time PCR;
D O I
10.1016/S0006-2952(03)00111-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 (CYP) drug metabolising enzymes CYP1A1 and CYP1B1 are regulated through the ligand-activated aryl L hydrocarbon (Ah) receptor. Differential expression of CYP1A1 and CYP1B1 mRNA and protein has previously been reported in human tissues with the presence of the message often extrapolated to indicate the presence of protein. The aim of this study was to clarify these potentially misleading findings, by analysing components of the Ah receptor pathway (CYP1B1, CYP1A1, Ah receptor and ARNT) using, a combination of quantitative real-time RT-PCR and immunoblotting. Three human cell lines (MOG-G-CCM, MCF7 and HEPG2) known to differentially express CYP1A1 and CYP1B1 mRNA and protein were exposed to the Ah receptor agonist 3-MC, and basal and inducible levels of CYP1A1, CYP1B1, Ah receptor and ARNT were determined. The key finding of this study was the demonstration of equivalent levels of CYP1B1 mRNA in both the treated and untreated MOG-G-CCM cell lines, with expression of the corresponding CYP I B I protein only after exposure to an Ah receptor agonist. This finding suggests that a post-transcriptional mechanism is involved in the regulation of CYP1B1. In addition, the expression pattern of CYP1B1 mRNA and protein in the MOG-G-CCM cells highlights this cell line as a potential model for studying CYP1B1 expression in human tissue. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1663 / 1674
页数:12
相关论文
共 41 条
[1]  
Bennett P, 1996, J CLIN PATHOL-CL MOL, V49, pM12
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   Characterization of the Ah receptor-associated protein, ARA9 [J].
Carver, LA ;
LaPres, JJ ;
Jain, S ;
Dunham, EE ;
Bradfield, CA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) :33580-33587
[4]   Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours [J].
Cheung, YL ;
Kerr, AC ;
McFadyen, MCE ;
Melvin, WT ;
Murray, GI .
CANCER LETTERS, 1999, 139 (02) :199-205
[5]  
CHRISTOU M, 1994, CARCINOGENESIS, V19, P291
[6]  
Coumoul X, 2001, CANCER RES, V61, P3942
[7]   Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans [J].
Edwards, RJ ;
Adams, DA ;
Watts, PS ;
Davies, DS ;
Boobis, AR .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (03) :377-387
[8]   Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin [J].
Giannone, JV ;
Li, W ;
Probst, M ;
Okey, AB .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (04) :489-497
[9]  
Grove D S, 1999, J Biomol Tech, V10, P11
[10]  
Huang ZQ, 1996, DRUG METAB DISPOS, V24, P899